Show simple item record

dc.contributor.authorPhilips, Leanne
dc.contributor.authorYoung, Megan K
dc.contributor.authorWallace, Janet
dc.contributor.authorDobinson, Hazel C
dc.date.accessioned2020-03-05T04:20:35Z
dc.date.available2020-03-05T04:20:35Z
dc.date.issued2020
dc.identifier.issn1034-4810
dc.identifier.doi10.1111/jpc.14800
dc.identifier.urihttp://hdl.handle.net/10072/392071
dc.description.abstractMeasles continues to be a public health concern world‐wide. Vulnerable individuals including those in which vaccinations is contraindicated, may be reliant on normal human immunoglobulin (NHIG) prophylaxis in an aim to prevent disease. This paper will summarise and discuss a tertiary paediatric hospital's clinical experience and the practicalities of administering intramuscular (IM) NHIG to paediatric patients as per the current measles prophylaxis guidelines in Australia. Following potential exposure within the emergency department, 17 paediatric patients (0–15 years) were recommended IM NHIG for prophylaxis. The dose of NHIG ranged from 0.6 to 15 mL and required multiple (2–8) injections. Two patients required sedation for staff to safely administer the injections. Staff involved with these cases reported administering multiple injections to paediatric patients to be a traumatising experience. They also expressed views that the injection of large volumes via the IM route was an impractical method of administration. Based on this experience, we recommend intravenous immunoglobulin be considered when large volumes of NHIG are recommended intramuscularly.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherWiley
dc.publisher.placeUnited Kingdom
dc.relation.ispartofjournalJournal of Paediatrics and Child Health
dc.subject.fieldofresearchPaediatrics
dc.subject.fieldofresearchReproductive medicine
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchHealth services and systems
dc.subject.fieldofresearchPublic health
dc.subject.fieldofresearchcode3213
dc.subject.fieldofresearchcode3215
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode4203
dc.subject.fieldofresearchcode4206
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsPediatrics
dc.subject.keywordsINJECTIONS
dc.titleClinical experience of intramuscular immunoglobulin for measles prophylaxis in children: Is it practical?
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationPhilips, L; Young, MK; Wallace, J; Dobinson, HC, Clinical experience of intramuscular immunoglobulin for measles prophylaxis in children: Is it practical?, Journal of Paediatrics and Child Health, 2020
dcterms.dateAccepted2020-01-16
dc.date.updated2020-03-02T01:28:58Z
dc.description.versionAccepted Manuscript (AM)
gro.description.notepublicThis publication has been entered into Griffith Research Online as an Advanced Online Version.
gro.rights.copyright© 2020 Paediatrics and Child Health Division (Royal Australasian College of Physicians). This is the peer reviewed version of the following article: Clinical experience of intramuscular immunoglobulin for measles prophylaxis in children: Is it practical?, Journal of Paediatrics and Child Health, which has been published in final form at 10.1111/jpc.14800. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
gro.hasfulltextFull Text
gro.griffith.authorYoung, Megan K.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record